The MRI-guided focused ultrasound therapy market size is expected to grow from US$ 441.73 million in 2025 to US$ 1,027.63 million by 2034; it is projected to register a CAGR of 10.0% during 2026-2034.

The rising prevalence of targeted diseases, technological advancements and regulatory approvals, and the shift towards noninvasive therapies and an aging population are noteworthy factors contributing to the expansion of the MRI-guided focused ultrasound therapy market size. Additionally, the development of portable and hybrid systems, and enhanced imaging and real-time thermometry are projected to bring new MRI-guided focused ultrasound therapy market trends in the near future.

The development of advanced imaging techniques together with instantaneous temperature measurement capabilities in MRgFUS treatment applications enables precise monitoring which guarantees safe and efficient tissue destruction through temperature mapping that requires no surgical intervention. The proton resonance frequency shift-based MR thermometry system accurately tracks HIFU temperature changes, which enables doctors to monitor their operations throughout the entire procedure. The PRF thermometry system in transcranial MRgFUS evaluates technical aspects of its clinical use to achieve precise monitoring of lesion development. The system relies on real-time ultrasound thermography (UST) which functions as an alternative to MR. The system uses graphics processing unit (GPU) technology to deliver economic monitoring solutions that operate at increased speeds while maintaining established monitoring methods which date back to the 1950s through its implementation after the medical field accepted MRgFUS technology. The system uses intelligence-based thermography (IT) technology to monitor FUS treatment while researchers assess new methods to oversee thermal management. MR thermometry in palliative MRgHIFU bone metastasis treatment provides better results in osteolytic bone-destroying lesions compared to upper body areas which show lower results according to evidence from multiple clinical treatments. The 7T MRI system enables real-time thermometry which monitors hyperthermia and drug delivery activities during treatment of patients, showing effective results in preclinical FUS systems. The techniques provide better protection as they enable exact procedures for both targeting and system supervision. The use of ultrasound-based solutions like UST provides a pathway to enhance the accessibility of image-guided FUS (IgFUS) technology which will promote its wider implementation. The advanced imaging method combines photoacoustic tomography with other techniques to achieve better tissue visualization results. Real-time thermometry helps predict and achieve controlled cell death patterns, in tumor treatments where excessive energy absorption must be avoided through careful and precise targeting, thereby emerging as a significant trend in the MRI-guided focused ultrasound therapy market.

End User-Based Insights

Based on end user, the MRI-guided focused ultrasound therapy market is segmented into healthcare facilities, diagnostic imaging centers, and research centers. The healthcare facilities segment held the largest MRI-guided focused ultrasound therapy market share in 2025. The healthcare facilities have adopted MR-guided focused ultrasound (MRgFUS) therapy as an essential treatment method because it enables hospitals and clinics to provide non-surgical solutions for patients who have essential tremor and Parkinson's disease and uterine fibroids and bone metastases. The Stanford Health Care facility has used MRgFUS since 2013 to treat essential tremor and Parkinson's disease and prostate cancer and bone metastases and uterine fibroids because it enables doctors to destroy specific body tissues while keeping adjacent areas intact according to their clinical program descriptions. The University of Maryland Medical Center (UMMC) developed MRgFUS as a treatment for essential tremor and Parkinson's-related tremors because its researchers conducted FDA clinical trials which led to system approval and now study its use for glioblastoma treatment in functional neurosurgery procedures. The UK-based Imperial College Healthcare NHS Trust applied MRgFUS through specialized equipment grants to treat essential tremor while using the technology to treat patients who have low-grade prostate cancer and uterine fibroids in outpatient settings.

Phased array technology enables skull penetration which allows brain procedures to occur without craniotomy, resulting in better patient outcomes and more efficient medical operations. The FDA approved uterine fibroid treatments in 2004 and bone metastasis treatments in 2012, which led to faster adoption of these procedures, while ongoing breast and liver and prostate cancer trials work toward achieving widespread clinical endorsement. This evolution supports multidisciplinary teams in delivering targeted therapy, minimizing hospital stays, and enhancing quality of life for patients with refractory conditions, thereby fueling the MRI-guided focused ultrasound therapy market growth.

The World Health Organization and Australian Institute of Health and Welfare are among the primary and secondary sources referred to while preparing the MRI-guided focused ultrasound therapy market report.